Home/Stock Analysis/LIMN

LIMN

Liminatus Pharma, Inc. Class A Common Stock

NASDAQ

Healthcare • Biotechnology

Updated 22 days ago

Coverage building

Factor tilt: Balanced Profile

Portfolio context

We’ll show you if LIMN is in your portfolio and how much it contributes.

Market context

Loading market dates

No dividend ex-date available

No 8-K filings in the last 30 days.

Smart money context

Institutional coverage is still building for this ticker.

Insider context

Sentiment: unknown

No recent insider trades detected.

Red flags: 0

Track CEO, CFO, and director trades

Why it matters

See which institutions own this stock

Why it matters

No red flags detected

Why it matters

Get the Full Analysis for LIMN

Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.